A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of Pf-06671008 In Patients With Advanced Solid Tumors

Trial Profile

A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of Pf-06671008 In Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs PF 6671008 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 14 Jan 2017 Planned End Date changed from 1 Jun 2019 to 1 Nov 2019.
    • 14 Jan 2017 Planned primary completion date changed from 1 Jun 2019 to 1 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top